SBIR/STTR Research Award
Combination of BA-210 and digestion of the glial scar in chronic spinal cord injury
Award amount
$319,201Program and phase
SBIR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIOAXONE BIOSCIENCES, INC.
- Proposal award date
- 2015-03-01
- Contract end date
- 2017-02-28
- UEI
- CK2GN49V59S4
- Solicitation number
- PA14-071
- Topic code
- 102
Research abstract
DESCRIPTION provided by applicant BA is an investigational drug that targets Rho an intracellular GTPase important for controlling axon regeneration and repair after spinal cord injury BA has completed a Phase I IIa clinical trial for treatment of acute spinal cord injury
in patients Not only was BA safe and well tolerated but patients with cervical SCI showed very promising recovery of arm and hand movements While current development is to treat acute spinal cord injury BA has potential to improve outcome in patients with chronic SCI especially if used in combination with other therapies One barrier to treating chronic SCI is
the glial scar that develops and remains after SCI Several drugs currently on the market have the potential to digest the glial scar and could be repurposed for SCI Combining BA with a repurposed drug will accelerate the regulatory path to clinical trials and approval The overall goal of this SBIR project is to investigate the use of BA in combination with one of two drugs that digest the glial scar as a treatment for chronic SCI
PUBLIC HEALTH RELEVANCE There are million Americans living with paralysis from spinal cord injury SCI and every year more become permanently paralyzed BA is a Rho antagonist in clinical development to treat acute SCI for chronic SCI combination therapies that digest the glial scar and promote regeneration provide the best strategy to improve recovery We propose to carry out proof of concept studies to test the efficacy of BA in combination with drugs that digest the glial scar for the treatment of chronic spinal cord injury
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- An oral ROCK2-selective inhibitor for treatment of chronic spinal cord injury
- Development of self-delivering RNAi targeted to PTEN for treatment of spinal cord injury
- Development of BA-1049 for treatment of cerebral cavernous malformation
- Development of BA for treatment of cerebral cavernous malformation
- Development of self-delivering RNAi to evaluate PTEN as a therapeutic target to p
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Research funding history
7 SBIR/STTR records share this UEI (2014–2018). Reported award amounts total $6,074,702. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services